Mar, 2018

U.S.A.
News / Corporate
U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that a supplemental New Drug Application (sNDA) for XTANDI®...
Read More

Feb, 2018

U.S.A.
News / Corporate
Astellas Acquires Universal Cells, Inc.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Universal Cells, Inc. (CEO: Claudia Mitchell, "Universal Cells") today announced that Astellas has acquired...
Read More

Jan, 2018

U.S.A.
News / Corporate
Astellas Reports Financial Results for the First Nine Months of FY2017
Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the financial results for the first nine months of fiscal year...
Read More
U.S.A.
News / Corporate
Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") today announced new data to be presented at the 2018 Genitourinary Cancers Symposium of the American Society of...
Read More
U.S.A.
News / Corporate
Astellas Completes Acquisition of Mitobridge, Inc.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas" ) today announced that it has completed the acquisition of Mitobridge, Inc. ("Mitobridge"), and Mitobridge has...
Read More